SCHEMBL6630248

SCHEMBL6630248

O=C(O)[C@@H](O)CS(=O)(=O)Cc1ccccc1OC(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.42
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 1/20 0.40
ALKBH1 Q13686 1/20 0.37
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
CYP2D6 P10635 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
TNF P01375 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6630252 1.00 HPGD (0.42) HPGDKMT2AMEN1ALDH1A1ALKBH1
SCHEMBL6651832 0.82 CTSS (0.40) HPGDKMT2A
SCHEMBL6629347 0.82 CTSS (0.40) HPGDKMT2A
SCHEMBL16815374 0.80 SMN1; SMN2 (0.48) KMT2AALKBH1PPARGPPARACYP2D6
SCHEMBL6630648 0.80 KMT2A (0.65) HPGDKMT2AMEN1ALDH1A1ALKBH1
SCHEMBL6692787 0.78 PPARG (0.36) HPGDKMT2AMEN1ALDH1A1ALKBH1
SCHEMBL6692785 0.78 PPARG (0.36) HPGDKMT2AMEN1ALDH1A1ALKBH1
SCHEMBL5696557 0.78 TNF (0.43) HPGDKMT2AMEN1ALDH1A1CYP2D6
SCHEMBL6629837 0.78 HPGD (0.39) HPGDKMT2AMEN1CA12CA1
SCHEMBL6062755 0.78 HPGD (0.39) HPGDKMT2AMEN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 US disclosed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP disclosed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE HPGD 1645/4885KMT2A 4623/4885MEN1 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.